Predicting Postoperative Recurrence Using a Support Vector Machine for Patients With Esophageal Squamous Cell Carcinoma: Machine Learning Modeling Development and Validation Study
JMIR Cancer · 2025
DOI: 10.2196/68027 ↗At a glance
Validierungsstudie in JMIR Cancer, 2025. Written by Meng Qing Xu and 11 co-authors. Institution: Department of Gastroenterology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 305, Zhongshan East Road, Nanjing, 2…. Major MEDLINE topics: Support Vector Machine, Neoplasm Recurrence, Local, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. 28 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
While numerous models have been developed to predict overall survival in postoperative patients with esophageal squamous cell carcinoma (ESCC), few have specifically focused on predicting postoperative recurrence.
Objective
This study aimed to develop and validate a support vector machine (SVM)-based predictive model for evaluating recurrence risk and identifying associated factors in ESCC patients following surgery.
Methods
We retrospectively analyzed clinical data from 311 ESCC patients who underwent surgery at Jinling Hospital between June 2014 and November 2016, with follow-up until October 2021 (median of 36 follow-up months, range 0-93.5 months). After excluding cases with incomplete data (n=1), 310 eligible patients were randomly allocated into test (n=106), validation 1 (n=103), and validation 2 (n=101) cohorts. Using SVM algorithms, patients were stratified into high- or low-recurrence-risk groups. Model performance was assessed using sensitivity, specificity, the Youden index, positive predictive value, and negative predictive value. Calibration curves were generated to evaluate model accuracy and reliability. Statistical analyses were performed using SPSS (version 22.0; IBM Corp) and R (version 3.6.1; R Foundation for Statistical Computing).
Results
In all cohorts, SVM7 (incorporating tumor node metastasis [TNM] stage, adjuvant therapy, differentiation, tumor size, and complications) demonstrated significantly higher sensitivity in predicting recurrence than SVM6 (based on the Eastern Cooperative Oncology Group performance status, neutrophil-to-lymphocyte ratio, and CY211) ( P
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Gastroenterology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 305, Zhongshan East Road, Nanjing, 210002, China, 86 17826080919.
- Department of Cardiothoracic Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Department of Gastroenterology, Jinling Hospital, Jinling School of Clinical Medicine, Nanjing Medical University, Nanjing, China.
ORCID profiles: Meng Qing Xu, Zhi Sheng Jiang, Wan Yu Liao, Ying Kang, Xiao Yue Feng, Kang Jiang, Qiong Jiang, Zhuang Zhuang Cong, Jing Luo, Lin Wu, Yi Shen, Fang Yu Wang
Cite
APA
Xu, M. Q., Jiang, Z. S., Liao, W. Y., Kang, Y., Feng, X. Y., Jiang, K., Jiang, Q., Cong, Z. Z., Luo, J., Wu, L., Shen, Y., & Wang, F. Y. (2025). Predicting Postoperative Recurrence Using a Support Vector Machine for Patients With Esophageal Squamous Cell Carcinoma: Machine Learning Modeling Development and Validation Study. JMIR Cancer. https://doi.org/10.2196/68027
Vancouver
Xu MQ, Jiang ZS, Liao WY, Kang Y, Feng XY, Jiang K, et al. Predicting Postoperative Recurrence Using a Support Vector Machine for Patients With Esophageal Squamous Cell Carcinoma: Machine Learning Modeling Development and Validation Study. JMIR Cancer. 2025. doi:10.2196/68027
BibTeX
@article{Xu2025,
author = {Xu, Meng Qing and Jiang, Zhi Sheng and Liao, Wan Yu and Kang, Ying and Feng, Xiao Yue and Jiang, Kang and Jiang, Qiong and Cong, Zhuang Zhuang and Luo, Jing and Wu, Lin and Shen, Yi and Wang, Fang Yu},
title = {Predicting Postoperative Recurrence Using a Support Vector Machine for Patients With Esophageal Squamous Cell Carcinoma: Machine Learning Modeling Development and Validation Study},
journal = {JMIR Cancer},
year = {2025},
doi = {10.2196/68027}
}
EUVIMED